Vasa Therapeutics secures FDA IND clearance to advance VS-041 into clinical trial for HFpEF
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Subscribe To Our Newsletter & Stay Updated